iSpecimen Inc. (NASDAQ: ISPC)

Sector: Healthcare Industry: Diagnostics & Research CIK: 0001558569
P/B 0.21
P/E -0.06
P/S 0.20
Market Cap 657,781.20
ROIC (Qtr) -568.97
Div Yield % 0.00
Rev 1y % (Qtr) -96.00
Total Debt (Qtr) 281,436.00
Debt/Equity (Qtr) 0.09

About

iSpecimen Inc., a technology-driven company that operates under the ticker symbol ISPC, is a significant player in the life science research industry. The company operates a global marketplace platform that connects researchers to subjects, specimens, and associated data, facilitating research, discovery, and development. The company's mission is to create a global marketplace for patients, biospecimens, and data to improve the quality of human life. iSpecimen's primary business activities revolve around procuring specimens from its healthcare...

Read more

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 2.78M provide 50.68x coverage of short-term debt 54904, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 3.94M provides 14x coverage of total debt 281436, indicating robust asset backing and low credit risk.
  • Tangible assets of 3.94M provide exceptional 25.34x coverage of deferred revenue 155506, showing strong service capability backing.
  • Operating cash flow of (6.90M) fully covers other non-current liabilities (155506) by 44.35x, showing strong long-term stability.
  • Tangible assets of 3.94M provide robust 4.52x coverage of other current liabilities 872384, indicating strong asset backing.

Cons

  • Investment activities of (1.07M) provide weak support for R&D spending of 2.58M, which is -0.42x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Operating cash flow of (6.90M) provides insufficient coverage of deferred revenue obligations of 155506, which is -44.35x, raising concerns about future service delivery capabilities.
  • The company's operating cash flow of (6.90M) shows concerning coverage of stock compensation expenses of 30473, with a -226.31 ratio indicating potential earnings quality issues.
  • Free cash flow of (7.97M) provides weak coverage of capital expenditures of 1.07M, with a -7.42 ratio suggesting additional external financing needs for growth initiatives.
  • Operating earnings of (11.37M) show weak coverage of depreciation charges of 1.68M, with a -6.77 ratio indicating high capital intensity and potential reinvestment needs.

Peer Comparison

Companies in the Diagnostics & Research
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 TMO Thermo Fisher Scientific Inc. 216.83 Bn 33.00 4.96 35.68 Bn
2 DHR Danaher Corp /De/ 162.47 Bn 46.38 6.69 16.86 Bn
3 IDXX Idexx Laboratories Inc /De 56.88 Bn 55.36 13.65 1.09 Bn
4 A Agilent Technologies, Inc. 39.82 Bn 32.64 5.87 3.41 Bn
5 IQV Iqvia Holdings Inc. 38.85 Bn 30.28 2.44 15.19 Bn
6 NTRA Natera, Inc. 31.32 Bn -101.29 14.80 0.18 Bn
7 MTD Mettler Toledo International Inc/ 28.99 Bn 34.68 7.35 2.21 Bn
8 WAT Waters Corp /De/ 22.92 Bn 35.32 7.38 1.49 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 0.04 2.69
EV to Cash from Ops. -0.05 18.14
EV to Debt 1.27 52.51
EV to EBIT -0.03 19.22
EV to EBITDA -0.03 4.35
EV to Free Cash Flow [EV/FCF] -0.04 2.84
EV to Market Cap 0.54 1.52
EV to Revenue 0.11 4.79
Price to Book Value [P/B] 0.21 1.34
Price to Earnings [P/E] -0.06 22.02

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -1.96
Dividend Payout Ratio % 0.00 2.83
Dividend per Basic Share 0.00 0.19
FCF Dividend Payout Ratio % 0.00 1.92
Interest Coverage -71.35 -126.58

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 35.69 -31.50
Cash and Equivalents Growth (1y) % 58.85 21.37
Dividend Growth (1y) % 0.00 0.24
EBIAT Growth (1y) % -19.68 -55.24
EBITDA Growth (1y) % -37.17 -447.96
EBIT Growth (1y) % -19.68 -40.50
EBT Growth (1y) % -21.10 -70.94
EPS Growth (1y) % 58.36 -70.02
FCF Growth (1y) % -32.50 56.33
Gross Profit Growth (1y) % -85.51 185.11

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.37 0.56
Cash Payout Ratio 0.00 0.01
Cash Ratio 0.49 1.21
Current Ratio 0.63 2.64
Debt to Equity Ratio 0.09 -0.80
Interest Cover Ratio -71.35 -126.58
Times Interest Earned -71.35 -126.58

Profitability

Metric Value Industry Percentile
EBITDA Margin % -289.10 -129.91
EBIT Margin % -339.24 -156.71
EBT Margin % -343.99 -162.23
Gross Margin % 21.60 47.70
Net Profit Margin % -344.00 -189.30